ETF · real data, updated daily
XBI — State Street Spdr S&P Biotech ETF
Over the last 15 years (2011-08 – 2026-09), $10,000 invested in XBI with dividends reinvested grew to $80,890 — 14.78% a year — with a worst peak-to-trough fall of -56.67%. Past performance doesn't predict future results.
Growth of $10,000 · 2011-08 – 2026-09 · dividends reinvested
About XBI
State Street SPDR S&P Biotech ETF is an exchange-traded fund that provides targeted exposure to U.S. biotechnology companies. It seeks to track the S&P Biotechnology Select Industry Index, using an equal-weighted approach that gives relatively balanced representation across the portfolio rather than concentrating heavily in the largest firms. The fund is designed for investors looking for broad access to the biotech segment of the healthcare market through a single security. Its holdings typically span drug developers, therapeutic innovators, life sciences tools companies, and other biotechnology businesses across different market-cap sizes. State Street SPDR S&P Biotech ETF is used by market participants to gain sector-specific exposure within healthcare, offering a diversified way to follow the performance of U.S. biotech equities within the broader financial market.
Put XBI to the test
Every tool below opens prefilled with XBI — free, no account needed.
Backtest XBI →
Full history, any date range, benchmarks, drawdowns, rolling returns.
Would XBI survive 2008? →
What actually happened to it in the crisis — real drawdown and recovery.
Project it forward →
Monte Carlo simulation of where it could go from here.
Compare XBI vs VTI →
Head-to-head against the total US market.
Replay $100/mo into XBI →
Animated growth of steady monthly contributions.
Fundamentals →
Holdings-level financials where available.
Educational use only — not investment advice. Results are hypothetical.Read full disclaimer
This tool is for educational and informational purposes only and does not provide financial, investment, tax, legal, or accounting advice. Results are hypothetical and based on historical data and assumptions that may be inaccurate. Past performance does not guarantee future results. Consult a licensed professional before making investment decisions.